CRF receptor antagonists and methods relating thereto

Details for Australian Patent Application No. 2004309168 (hide)

Owner Neurocrine Biosciences Inc SmithKline Beecham (Cork) Limited

Inventors Williams, John; Slee, Deborah; Luo, Zhiyong; Zhang, Xiahou; Tellew, John Edward

Agent Davies Collison Cave

Pub. Number AU-B-2004309168

PCT Pub. Number WO2005/063755

Priority 60/532,031 22.12.03 US

Filing date 20 December 2004

Wipo publication date 14 July 2005

Acceptance publication date 23 April 2009

International Classifications

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

29 June 2006 PCT application entered the National Phase

  PCT publication WO2005/063755 Priority application(s): WO2005/063755

30 October 2008 Assignment before Grant

  SB Pharmco Puerto Rico Inc; Neurocrine Biosciences Inc The application has been assigned to Neurocrine Biosciences Inc; SmithKline Beecham (Cork) Limited

23 April 2009 Application Accepted

  Published as AU-B-2004309168

20 August 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004309170-Nature-identical Erythropoietin

2004309166-Novel quinoline derivatives